98%
921
2 minutes
20
: The aim of this article is to present a single-surgeon, open retroperitoneal lymph node dissection (RPLND) series for testicular cancer in a high-volume center. : We reviewed data from patients who underwent RPLND performed by an experienced surgeon at our institution between 2000 and 2019. We evaluated surgical and perioperative outcomes, complications, Recurrence-Free Survival (RFS), Overall Survival (OS), and Cancer-Specific Survival (CSS). : RPLND was performed in primary and secondary settings in 21 (32%) and 44 (68%) patients, respectively. Median operative time was 180 min. Median hospital stay was 6 days. Complications occurred in 23 (35%) patients, with 9 (14%) events reported as Clavien grade ≥ 3. Patients in the primary RPLND group were significantly younger, more likely to have NSGCT, had higher clinical N0 and M0, and had higher nerve-sparing RPLND (all ≤ 0.04) compared to those in the secondary RPLND group. In the median follow-up of 120 (56-180) months, 10 (15%) patients experienced recurrence. Finally, 20-year OS, CSS, and RFS were 89%, 92%, and 85%, respectively, with no significant difference in survival rates between primary vs. secondary RPLND subgroups ( = 0.64, = 0.7, and = 0.31, respectively). : Open RPLND performed by an experienced high-volume surgeon achieves excellent oncological and functional outcomes supporting the centralization of these complex procedures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865264 | PMC |
http://dx.doi.org/10.3390/medicina59010133 | DOI Listing |
Urologie
August 2025
Department of Urology, Indiana University School of Medicine, 340 W 10th St, 46202, Indianapolis, IN, USA.
Retroperitoneal lymph node dissection (RPLND) plays a critical role in the multidisciplinary management of advanced testicular cancer. Cisplatin-based chemotherapy regimens have been the cornerstone of treatment for these patients. Long-term toxicity and secondary malignancy in patients receiving cisplatin, along with surgical advancements, have encouraged providers to revisit the role of primary RPLND for patients with stage IIA/B germ cell tumor.
View Article and Find Full Text PDFUrol Case Rep
September 2025
Dept. of Interventional Radiology, QEUH, 1345 Govan Rd, Glasgow, G51 4TF, UK.
Retroperitoneal lymph node dissection (RPLND) is a procedure with both diagnostic and therapeutic benefits. We present a patient who underwent retroperitoneal lymph node dissection for a PET-positive left para-aortic lymph node identified on surveillance. Subsequently developing chylous ascites.
View Article and Find Full Text PDFAnn Surg Oncol
July 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Background: Mesothelioma of the tunica vaginalis testes (testicular mesothelioma [TM]) is a rare tumor, comprising less than 5% of mesotheliomas. Surgical intervention is the current standard of care, whereas the role of systemic therapies remains undefined.
Methods: We retrospectively reviewed 36 patients with pathologically confirmed TM treated at Memorial Sloan Kettering Cancer Center (MSK) between January 1996 to May 2023.
BMC Urol
July 2025
Department of Urology, Royal North Shore Hospital, St Leonards, NSW, Australia.
Background: To detail the outcomes of an open midline extraperitoneal (midline EP) approach to post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic testicular cancer.
Methods: We analysed our prospectively maintained operative database from April 2020 to February 2023 for cases of midline EP approach to PC-RPLND, identifying a total of 11 patients across two hospitals in Sydney, Australia. Demographic and perioperative data was obtained from electronic medical records, including preoperative factors such as cancer staging and preoperative treatment.
Eur J Surg Oncol
August 2025
Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy.
Introduction: Retroperitoneal lymph node dissection (RPLND) is an integral part of the multidisciplinary treatment of Testis cancer (TC). Up to now, only few studies compared traditional open RPLND (O-RPLND) with minimally invasive approach. We investigated surgical outcomes and complication rates of patient with TC treated with O-RPLND or robot assisted (RA-RPLND).
View Article and Find Full Text PDF